NGEN

+ Watchlist + Portfolio

NervGen Pharma Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.75
52-Week Range: $1.58 – $6.30
Market Cap: $189.24M
P/E (TTM): —
EPS (TTM): -0.57
Dividend Yield: —

Advanced Metrics

Price/Book: 13.06
PEG Ratio: —
Return on Equity: -757.48%
Return on Assets: -37.70%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.23
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $38.18M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $74.99M

NGEN Income statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$16.61M	$8.05M	$15.81M	$13.91M
Selling, General & Admin	$6.34M	$9.63M	$9.34M	$11.17M
Operating Expenses	$23.03M	$17.78M	$25.18M	$25.08M
Operating Income	-$23.03M	-$17.78M	-$25.18M	-$25.08M
EBITDA	-$20.09M	-$17.63M	-$25.09M	-$25.02M
Pretax Income	-$20.72M	-$22.38M	-$24.25M	-$44.12M
Net Income	-$20.72M	-$22.38M	-$24.25M	-$44.12M
Diluted EPS	-0.39	-0.38	-0.36	-0.61
Diluted Shares	52.65M	59.29M	67.32M	72.33M

NGEN Balance Sheet statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$22.45M	$11.66M	$17.27M	$22.07M
Receivables	$27.03K	$250.21K	$415.30K	$80.83K
Current Assets	$23.15M	$12.52M	$19.01M	$22.80M
Total Assets	$23.88M	$13.24M	$19.49M	$23.21M
Current Liabilities	$10.22M	$15.14M	$16.90M	$19.73M
Total Debt	$283.45K	$197.19K	$105.60K	$8.37K
Total Liabilities	$10.41M	$15.25M	$16.91M	$19.73M
Retained Earnings	-$55.77M	-$78.15M	-$102.65M	-$146.76M
Shareholders' Equity	$13.46M	-$2.01M	$2.58M	$3.48M
Working Capital	$12.93M	-$2.62M	$2.11M	$3.07M

NGEN Cash Flow statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.78M	-$11.30M	-$16.84M	-$19.50M
Capital Expenditure	-$21.11K	-$141.40K	—	—
Free Cash Flow	-$17.81M	-$11.44M	-$16.84M	-$19.50M
Depreciation & Amortisation	$115.11K	$145.00K	$83.80K	$55.80K
Stock-Based Compensation	$2.77M	$6.04M	$6.04M	$5.39M
Investing Cash Flow	-$21.11K	-$138.85K	$58.87K	$100.93K
Financing Cash Flow	$22.64M	$766.28K	$22.70M	$23.76M
Net Change in Cash	$4.84M	-$10.67M	$5.91M	$4.37M

NGEN Income statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.15M	$2.71M	$4.44M	$3.60M	$4.86M
Selling, General & Admin	$2.89M	$3.76M	$1.73M	$2.80M	$2.67M
Operating Expenses	$6.04M	$6.47M	$6.17M	$6.40M	$7.53M
Operating Income	-$6.04M	-$6.47M	-$6.17M	-$6.40M	-$7.53M
EBITDA	-$6.02M	-$6.46M	-$6.16M	-$6.39M	-$7.53M
Pretax Income	-$3.95M	-$9.10M	-$4.16M	-$26.91M	-$1.68M
Net Income	-$3.95M	-$9.10M	-$4.16M	-$26.91M	-$1.68M
Diluted EPS	-0.06	-0.13	-0.06	—	-0.09
Diluted Shares	70.67M	71.96M	73.16M	—	80.86M

NGEN Balance Sheet statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$17.27M	$14.47M	$15.67M	$11.36M	$22.07M
Receivables	$415.30K	$333.77K	$96.95K	$344.20K	$80.83K
Current Assets	$19.01M	$15.39M	$16.49M	$12.65M	$22.80M
Total Assets	$19.49M	$15.84M	$16.92M	$13.08M	$23.21M
Current Liabilities	$16.90M	$14.45M	$17.84M	$16.02M	$19.73M
Total Debt	$105.60K	$81.84K	$57.71K	$33.23K	$8.37K
Total Liabilities	$16.91M	$14.45M	$17.84M	$16.02M	$19.73M
Retained Earnings	-$102.65M	-$106.11M	-$115.21M	-$119.85M	-$146.76M
Shareholders' Equity	$2.58M	$1.39M	-$918.42K	-$2.94M	$3.48M
Working Capital	$2.11M	$938.47K	-$1.36M	-$3.36M	$3.07M

NGEN Cash Flow statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.66M	-$4.12M	-$3.67M	-$5.32M	-$6.40M
Free Cash Flow	-$3.66M	-$4.12M	-$3.67M	-$5.32M	-$6.40M
Depreciation & Amortisation	$15.81K	$13.95K	$13.95K	$13.95K	$13.95K
Stock-Based Compensation	$1.67M	$1.46M	$2.02M	$1.11M	$802.53K
Investing Cash Flow	$25.23K	$25.23K	$25.23K	$25.23K	$25.23K
Financing Cash Flow	$310.00K	$1.27M	$4.75M	$995.20K	$16.74M
Net Change in Cash	-$3.32M	-$2.82M	$1.11M	-$4.30M	$10.37M

Market Snapshot

About

NervGen Pharma is a clinical-stage biotech company developing treatments for nerve damage and spinal cord injuries. The company focuses on therapies that promote nerve regeneration and repair using its proprietary platform, targeting conditions including traumatic spinal cord injury, multiple sclerosis, and peripheral nerve damage.